
Biotechnology & ‘Fog of Valuation’ savant
| Platform | Pricing | Freemium | Publishes | Twice weekly | |
|---|---|---|---|---|---|
| Issues | 71 | Subscribers | Read | hartajsingh1.substack.com |
Curious about how many subscribers The Biotech Capital Compass has or want to find similar newsletters? Reletter has got you covered. We collated all the information we could find from across the web in our database of over three million newsletters.
Check the email archives, get traffic estimates, engagement scores and more to discover the best advertising opportunities.
Our search tool helps you locate relevant newsletters for any topic and compare their stats for better sponsorship decisions.
Recent posts by this newsletter. Browse the email archive.
With overwhelmingly positive IPF results, Tyvaso could become the first inhaled therapy for a disease long defined by limited options, and Wall Street took notice.
Resilient momentum emerges amid compressed multiples and uneven sector leadership.
Promise of a first-in-class therapy, but history cautions patience.
Broad catalysts support long-term value, but near-term execution—Eylea stabilization, earnings momentum, and reliance on partners—must improve before a premium multiple returns.
Other publications recommended by the authors of this newsletter.
The writers behind this newsletter.
Biotech veteran with 30+ years in the field, including 15+ as a BioPharma investor. I bring a Wall Street lens to biotech—with a mission to inform, inspire, and support. 10–20% of paid subs help fund fellow Substack creatives. \ud83d\udc97
PhD scientist, consultant. Subscribe for biotechnology & pharma newsletter and science deep dives.
You can find recent issues that have been published by The Biotech Capital Compass on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.
To see how many people subscribe to The Biotech Capital Compass, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.
Newsletter advertising can be extremely effective when it's done right. Before you pitch The Biotech Capital Compass as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.
Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.
Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.
To find out how much an ad will cost, contact The Biotech Capital Compass using the contact information provided and ask for a copy of their media kit.
Scroll up to where it says Similar Newsletters to see other publications like The Biotech Capital Compass. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.
Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.